Therefore, a range of HDAC inhibitors (HDACis) have been developed for cancer intervention over the past two decades, and have received clinical approval (e.g. belinostat, vorinostat) or are undergoing clinical trials (entinostat). The gene discussed is HDAC9; the disease is cancer.